All In Biotech

NDA 022042 · Lilly

Evista

Raloxifene Hydrochloride · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Sep 13, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Sep 13, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

69

19 Phase 3, 4 recruiting

FAERS reports

14,534

8,238 serious, 560 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • EVISTA · RALOXIFENE HYDROCHLORIDE 60MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Raloxifene" as an intervention, any sponsor and status, largest first.

All 69 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea777
  • fall772
  • drug ineffective751
  • pain in extremity717
  • pain686
  • arthralgia637
  • dizziness615
  • muscle spasms588
  • fatigue565
  • headache557
  • body height decreased532
  • back pain470

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,125
2005990
2006855
2007715
2008758
2009743
2010793
2011621
2012757
2013530
2014554
20153,688
2016471
2017429
2018325
2019291
2020205
2021165
2022145
2023113
202499
202596
202665

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Evista (Raloxifene HCl)

2024 spending

$925K

Beneficiaries

527

2,355 claims

Per beneficiary

$1,755

$6.24 per unit

View as table
YearSpending
2020$1,994,285
2021$1,622,729
2022$1,321,400
2023$1,164,041
2024$924,682

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 644 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.